文献速递消化道肿瘤与早癌

随机临床研究:每日口服阿司匹林325 mg与安慰剂对比改变肠道微生物组成及与结直肠癌风险相关的细菌分类群

Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk.
PubMed 文献 · Aliment Pharmacol Ther · 2020-08-08

在50-75岁健康志愿者中开展的雙盲随机安慰剂对照先导试验,阿司匹林325 mg组30例、安慰剂组20例每日一次共6周,每3周采集粪便至12周。阿司匹林组与安慰剂组相比微生物组成存在差异,四个分类群在两组间丰度不同,部分与结直肠癌相关的细菌分类群变化方向与预设假设一致。作者认为阿司匹林可能通过影响肠道微生物组影响结直肠癌发生,但需在更大试验中重复验证。

要点

  • 阿司匹林325 mg每日一次共6周可改变健康成人肠道微生物组成。
  • 阿司匹林组与安慰剂组间四个分类群丰度存在差异:普雷沃菌属、韦荣球菌属、梭菌XlVa群和梭菌XVIII群。
  • 与结直肠癌相关的细菌分类群变化方向与预设假设一致,但需更大试验重复验证。

核心结论

  • 与安慰剂相比,阿司匹林摄入影响若干微生物分类群(瘤胃球菌科、梭菌XlVa群、副拟杆菌属和Dorea),其变化方向与基于这些分类群与结直肠癌关联的预设假设一致。
  • 这提示阿司匹林可能通过影响肠道微生物组影响结直肠癌发生。
  • 该发现需在更大试验中重复验证。

研究设计与样本

  • 双盲、随机、安慰剂对照先导试验。
  • 健康志愿者年龄50-75岁,接受标准剂量阿司匹林325 mg(N=30)或安慰剂(N=20),每日一次,共6周。
  • 每3周提供粪便样本,共12周。
  • 通过16S rRNA序列获得肠道微生物群落组成和细菌丰度的系列测量。
  • 采用线性判别分析效应大小(LEfSe)检验组间细菌丰度差异;采用二项分布的混合效应回归,通过交互项(治疗×时间)估计阿司匹林使用对单个细菌分类群相对丰度变化的影响。

主要发现

  • 研究期间,阿司匹林组与安慰剂组相比微生物组成存在差异。
  • 治疗后,四个分类群在两组间丰度不同:普雷沃菌属(Prevotella)、韦荣球菌属(Veillonella)、梭菌XlVa群(Clostridium XlVa)和梭菌XVIII群(Clostridium XVIII)。
  • 在已发表研究中与结直肠癌相关(n=8)或与阿司匹林摄入相关(n=4)的预设细菌中,四个分类群的交互作用显著,提示阿司匹林组与安慰剂组相比,Akkermansia、普雷沃菌属和瘤胃球菌科相对增加,副拟杆菌属、拟杆菌属和Dorea相对减少。

关键数值与推荐

  • 阿司匹林剂量为325 mg,每日一次,共6周。
  • 粪便样本每3周采集一次,共12周。
  • 与结直肠癌相关(n=8)或与阿司匹林摄入相关(n=4)的预设细菌分类群用于分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出该发现需在更大试验中重复验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aspirin is associated with decreased risk of colorectal cancer (CRC), potentially by modulating the gut microbiome. AIMS: To evaluate the effect of aspirin on the gut microbiome in a double-blinded, randomised placebo-controlled pilot trial. METHODS: Healthy volunteers aged 50-75 received a standard dose of aspirin (325 mg, N = 30) or placebo (N = 20) once daily for 6 weeks and provided stool samples every 3 weeks for 12 weeks. Serial measurements of gut microbial community composition and bacterial abundance were derived from 16S rRNA sequences. Linear discriminant analysis of effect size (LEfSe) was tested for between-arm differences in bacterial abundance. Mixed-effect regression with binomial distribution estimated the effect of aspirin use on changes in the relative abundance of individual bacterial taxa via an interaction term (treatment × time). RESULTS: Over the study period, there were differences in microbial composition in the aspirin vs placebo arm. After treatment, four taxa were differentially abundant across arms: Prevotella, Veillonella, Clostridium XlVa and Clostridium XVIII clusters. Of pre-specified bacteria associated with CRC (n = 8) or aspirin intake (n = 4) in published studies, interactions were significant for four taxa, suggesting relative increases in Akkermansia, Prevotella and Ruminococcaceae and relative decreases in Parabacteroides, Bacteroides and Dorea in the aspirin vs placebo arm. CONCLUSION: Compared to placebo, aspirin intake influenced several microbial taxa (Ruminococcaceae, Clostridium XlVa, Parabacteroides and Dorea) in a direction consistent with a priori hypothesis based on their association with CRC. This suggests that aspirin may influence CRC development through an effect on the gut microbiome. The findings need replication in a larger trial.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Prizment AE, Staley C, Onyeaghala GC, et al. Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk. Aliment Pharmacol Ther. 2020. PMID: 32770859. doi:10.1111/apt.16013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。